Legend Biotech stock gains after strong quarterly figures

Legend Biotech Corporation (US52490G1022) closed at USD 17.61 on Nasdaq on September 18, 2026, gaining 0.17 percent from the prior session. The company remains tied to CARVYKTI, its multiple myeloma therapy, while updated clinical data provide the clearest current operating reference.

CARVYKTI data remain central

According to NovaPharmaNews on September 22, 2026, Legend Biotech presented updated survival and safety results for CARVYKTI from the CARTITUDE-4 study at ASCO 2026. The report also identifies LB2501 as an experimental in vivo CAR-T program and states that all treated lymphoma patients in the first-in-human trial showed reduced or eliminated disease signs.

That operating detail matters because the stock price remains low in absolute terms at USD 17.61, while the available company coverage centers on clinical execution rather than a new financial forecast. The comparison is concrete: the September 18 close was USD 0.03 above the prior session, equivalent to a 0.17 percent daily gain.

Trading data set the reference

The latest identified Nasdaq close was recorded at 4:00 p.m. Eastern time on September 18, 2026. The same company-specific market snapshot identifies Legend Biotech Corporation, ticker LEGN, as a Nasdaq-listed biotechnology company and confirms the ISIN US52490G1022.

For investors, the combination of a modest one-day move and fresh clinical discussion leaves the operating narrative concentrated on CARVYKTI and the pipeline. The available evidence supports a factual reading of the stock, but not a new price target or rating claim.

Legend Biotech stock closes at USD 17.61

Legend Biotech stock closed at USD 17.61 on Nasdaq at 4:00 p.m. Eastern time on September 18, 2026, up 0.17 percent on the session. The dated quote is the reference value for this article.

More news and analyses on Legend Biotech stock